Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

In vivo near-infrared spectroscopy and magnetic resonance imaging monitoring of tumor response to combretastatin A-4-phosphate correlated with therapeutic outcome.

Zhao D, Chang CH, Kim JG, Liu H, Mason RP.

Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):574-81. doi: 10.1016/j.ijrobp.2010.12.028. Epub 2011 Feb 23.

2.

Combretastatin A4 phosphate: a novel vascular disrupting agent.

Nagaiah G, Remick SC.

Future Oncol. 2010 Aug;6(8):1219-28. doi: 10.2217/fon.10.90. Review.

PMID:
20799867
3.

Combretastatin A4 phosphate.

West CM, Price P.

Anticancer Drugs. 2004 Mar;15(3):179-87. Review.

PMID:
15014350
4.

A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).

Siemann DW, Chaplin DJ, Walicke PA.

Expert Opin Investig Drugs. 2009 Feb;18(2):189-97. doi: 10.1517/13543780802691068 . Review.

5.

Combretastatin A4 phosphate: background and current clinical status.

Young SL, Chaplin DJ.

Expert Opin Investig Drugs. 2004 Sep;13(9):1171-82. Review.

PMID:
15330748
6.

Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status.

Jaroch K, Karolak M, Górski P, Jaroch A, Krajewski A, Ilnicka A, Sloderbach A, Stefański T, Sobiak S.

Pharmacol Rep. 2016 Dec;68(6):1266-1275. doi: 10.1016/j.pharep.2016.08.007. Epub 2016 Aug 24. Review.

PMID:
27686966

Supplemental Content

Support Center